Quotes 5-day view Delayed Nasdaq
01/13/2021
01/14/2021
01/15/2021
01/19/2021
01/20/2021
Date
227.1(c)
226.12(c)
225.55(c)
231.91(c)
236.7(c)
Last
1 809 591
1 728 068
2 242 187
2 044 843
1 608 815
Volume
-0.99% -0.43% -0.25% +2.82% +2.07% Change
Sales 2020
6 157 M - -
Net income 2020
2 607 M - -
Net cash position 2020
5 869 M - -
P/E ratio 2020
23,9x
Yield 2020
-
Sales 2021
6 930 M - -
Net income 2021
2 669 M - -
Net cash position 2021
9 152 M - -
P/E ratio 2021
23,4x
Yield 2021
-
Capitalization
61 551 M 61 551 M -
EV / Sales 2020
9,04x
EV / Sales 2021
7,56x
Nbr of Employees
3 000
Free-Float
72,2%
Vertex Pharmaceuticals specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales break down by type of income as follows:
- income from sales of products (99.9%);
- royalties and income from partnership, research, and development agreements (0.1%).
Net sales break down geographically as follows:...
Notations Surperformance© of Vertex Pharmaceuticals
Trading Rating : Investor Rating :
All news about VERTEX PHARMACEUTICALS
News in other languages on VERTEX PHARMACEUTICALS
Analyst Recommendations on VERTEX PHARMACEUTICALS
Chart VERTEX PHARMACEUTICALS
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends VERTEX PHARMACEUTICALS
Short Term Mid-Term Long Term Trends Neutral Bearish Neutral
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
BUY
Number of Analysts
28
Average target price
286,12 $
Last Close Price
236,70 $
Spread / Highest target
44,9%
Spread / Average Target
20,9%
Spread / Lowest Target
-7,06%
Please enable JavaScript in your browser's settings to use dynamic charts.
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
